Carvedilol | Vedicardol tablets 6.25 mg, 30 pcs.
Special Price
$15.52
Regular Price
$23.00
In stock
SKU
BID464762
Release form
Tablets
Tablets
Release form
Tablets
Packing
30 pcs. packaged.
Pharmacological action
Alpha and beta blocker. Carvedilol has a combined non-selective effect due to blockade of 1-, 2- and 1-adrenergic receptors. The drug does not have its own sympathomimetic activity, has membrane-stabilizing properties. Thanks to the blockade of β-adrenoreceptors of the heart, blood pressure decreases, cardiac output and heart rate decrease.
Carvedilol suppresses the renin-angiotensin-aldosterone system by blocking the renal adrenergic receptors, causing a decrease in plasma renin activity. By blocking adrenergic receptors, the drug can cause the expansion of peripheral vessels, thereby reducing OPSS.
The combination of blockade - adrenergic receptors and vasodilation has the following effects: in case of arterial hypertension - lowering blood pressure in coronary heart disease - antianginal effect in patients with left ventricular dysfunction and circulatory failure favorably affects hemodynamic parameters, increases the ejection fraction of the left ventricle and helps to reduce its size.
Indications
- arterial hypertension (as monotherapy and in combination with diuretics)
- coronary heart disease: stable angina pectoris
- chronic heart failure (as part of combination therapy).
Contraindications
- acute heart failure
- chronic heart failure (at the stage of decompensation)
- severe liver failure
- AV block II-III degree
- severe bradycardia (less than 50 beats. / min)
- SSSU
- arterial hypotension (systolic blood pressure less than 85 mm Hg)
- cardiogenic shock
- chronic obstructive pulmonary disease
- under 18 years of age (efficacy and safety not established)
- hypersensitivity to components the drug.
Caution should be used for Prinzmetal angina pectoris, thyrotoxicosis, peripheral vascular occlusion diseases, pheochromocytoma, psoriasis, renal failure, grade I AV block, for extensive surgical interventions and general anesthesia, for diabetes mellitus, hypoglycemia, depression, myasthenia gravis.
Use during pregnancy and lactation
There are no adequate and strictly controlled clinical trials on the safety of using Vedicardol during pregnancy, therefore, the appointment of the drug during pregnancy is possible only when the intended benefit to the mother outweighs the potential risk to the fetus.
During the treatment with carvedilol, breastfeeding is not recommended.
Special instructions
Therapy should be carried out for a long time and not stop abruptly, especially in patients with coronary artery disease. this can lead to a deterioration in the course of the underlying disease. If necessary, the dose reduction should be gradual, within 1-2 weeks.
At the beginning of therapy with Vedicardol or with an increase in the dose of the drug in patients, especially the elderly, an excessive decrease in blood pressure may occur, mainly when standing up. A dose adjustment is necessary. In patients with chronic heart failure, dose selection may increase symptoms of heart failure, the appearance of edema. In this case, the dose of Vedicardol should not be increased, it is recommended that large doses of diuretics be prescribed up to the stabilization of the patient's condition.
Recommended continuous monitoring of ECG and blood pressure with the simultaneous administration of Vedicardol and slow calcium channel blockers, phenylalkylamine derivatives (verapamil), benzodiazepine derivatives (diltiazem), and also with class I antiarrhythmic drugs.
It is recommended to monitor renal function in patients with chronic renal failure, arterial hypotension, and chronic heart failure.
If surgery is performed using general anesthesia, the anesthetist should be advised of prior therapy with Vedicardol.
Vedicardol does not affect blood glucose concentration and does not cause changes in glucose tolerance test parameters in patients with non-insulin-dependent diabetes mellitus.
Patients with pheochromocytoma must be prescribed alpha-blockers before starting therapy.
When prescribed to patients using contact lenses, it should be borne in mind that the drug may cause a decrease in lacrimation.
Avoid ethanol during treatment.
Influence on the ability to drive vehicles and control mechanisms
It is not recommended to drive a car at the beginning of therapy and with an increase in the dose of Vedicardol. You should refrain from other activities, associated with the need for a high concentration of attention and quick psychomotor reactions.
Composition
Active ingredient: carvedilol 6.25 mg.
Excipients: microcrystalline cellulose, calcium stearate, crospovidone, talc, lactose monohydrate.
Drug Interactions
Carvedilol may potentiate the effects of other simultaneously taken antihypertensive drugs or drugs that have a hypotensive effect (nitrates).
With the combined use of carvedilol and diltiazem, cardiac conduction disturbances and hemodynamic disturbances may develop.
With the simultaneous administration of carvedilol and digoxin, the concentration of the latter increases and the time of AV administration may increase.
Carvedilol can potentiate the effects of insulin and oral hypoglycemic agents, while the symptoms of hypoglycemia (especially tachycardia) can be masked, so it is recommended that patients with diabetes have regular monitoring of blood sugar levels.
Microsomal oxidation inhibitors (cimetidine) enhance and inducers (phenobarbital, rifampicin) weaken the hypotensive effect of carvedilol.
Catecholamine-lowering drugs (reserpine, MAO inhibitors) increase the risk of hypotension and severe bradycardia.
With the simultaneous use of cyclosporine, the concentration of the latter increases (correction of the daily dose of cyclosporine is recommended).
Concomitant administration of clonidine can potentiate the antihypertensive and heart-rate-reducing effects of carvedilol.
General anesthetics enhance the negative inotropic and hypotensive effect of carvedilol.
Overdose
Symptoms: decreased blood pressure (accompanied by dizziness or fainting), bradycardia. Shortness of breath due to bronchospasm and vomiting may occur. In severe cases cardiogenic shock, respiratory distress, confusion, conductivity disorders are possible.
Treatment: It is necessary to monitor and correct vital indicators, if necessary - in OIT. Symptomatic therapy is carried out. It is advisable to / in the introduction of m-cholin blockers (atropine), adrenomimetics (epinephrine, norepinephrine).
Storage Conditions
The product should be stored out of the reach of children, in a dry, dark place at a temperature not exceeding 25 РC.
Shelf life
2 years.
Terms and conditions
prescription
dosage form
tablets
Possible product names
Vedicardol 6.25mg No. 30
Vedicardol 6.25mg Tab. X30 (R)
VEDICARDOL TAB. 6.25MG No. 30
Vedicardol tablets 6.25 mg, 30 pcs.
Tablets
Packing
30 pcs. packaged.
Pharmacological action
Alpha and beta blocker. Carvedilol has a combined non-selective effect due to blockade of 1-, 2- and 1-adrenergic receptors. The drug does not have its own sympathomimetic activity, has membrane-stabilizing properties. Thanks to the blockade of β-adrenoreceptors of the heart, blood pressure decreases, cardiac output and heart rate decrease.
Carvedilol suppresses the renin-angiotensin-aldosterone system by blocking the renal adrenergic receptors, causing a decrease in plasma renin activity. By blocking adrenergic receptors, the drug can cause the expansion of peripheral vessels, thereby reducing OPSS.
The combination of blockade - adrenergic receptors and vasodilation has the following effects: in case of arterial hypertension - lowering blood pressure in coronary heart disease - antianginal effect in patients with left ventricular dysfunction and circulatory failure favorably affects hemodynamic parameters, increases the ejection fraction of the left ventricle and helps to reduce its size.
Indications
- arterial hypertension (as monotherapy and in combination with diuretics)
- coronary heart disease: stable angina pectoris
- chronic heart failure (as part of combination therapy).
Contraindications
- acute heart failure
- chronic heart failure (at the stage of decompensation)
- severe liver failure
- AV block II-III degree
- severe bradycardia (less than 50 beats. / min)
- SSSU
- arterial hypotension (systolic blood pressure less than 85 mm Hg)
- cardiogenic shock
- chronic obstructive pulmonary disease
- under 18 years of age (efficacy and safety not established)
- hypersensitivity to components the drug.
Caution should be used for Prinzmetal angina pectoris, thyrotoxicosis, peripheral vascular occlusion diseases, pheochromocytoma, psoriasis, renal failure, grade I AV block, for extensive surgical interventions and general anesthesia, for diabetes mellitus, hypoglycemia, depression, myasthenia gravis.
Use during pregnancy and lactation
There are no adequate and strictly controlled clinical trials on the safety of using Vedicardol during pregnancy, therefore, the appointment of the drug during pregnancy is possible only when the intended benefit to the mother outweighs the potential risk to the fetus.
During the treatment with carvedilol, breastfeeding is not recommended.
Special instructions
Therapy should be carried out for a long time and not stop abruptly, especially in patients with coronary artery disease. this can lead to a deterioration in the course of the underlying disease. If necessary, the dose reduction should be gradual, within 1-2 weeks.
At the beginning of therapy with Vedicardol or with an increase in the dose of the drug in patients, especially the elderly, an excessive decrease in blood pressure may occur, mainly when standing up. A dose adjustment is necessary. In patients with chronic heart failure, dose selection may increase symptoms of heart failure, the appearance of edema. In this case, the dose of Vedicardol should not be increased, it is recommended that large doses of diuretics be prescribed up to the stabilization of the patient's condition.
Recommended continuous monitoring of ECG and blood pressure with the simultaneous administration of Vedicardol and slow calcium channel blockers, phenylalkylamine derivatives (verapamil), benzodiazepine derivatives (diltiazem), and also with class I antiarrhythmic drugs.
It is recommended to monitor renal function in patients with chronic renal failure, arterial hypotension, and chronic heart failure.
If surgery is performed using general anesthesia, the anesthetist should be advised of prior therapy with Vedicardol.
Vedicardol does not affect blood glucose concentration and does not cause changes in glucose tolerance test parameters in patients with non-insulin-dependent diabetes mellitus.
Patients with pheochromocytoma must be prescribed alpha-blockers before starting therapy.
When prescribed to patients using contact lenses, it should be borne in mind that the drug may cause a decrease in lacrimation.
Avoid ethanol during treatment.
Influence on the ability to drive vehicles and control mechanisms
It is not recommended to drive a car at the beginning of therapy and with an increase in the dose of Vedicardol. You should refrain from other activities, associated with the need for a high concentration of attention and quick psychomotor reactions.
Composition
Active ingredient: carvedilol 6.25 mg.
Excipients: microcrystalline cellulose, calcium stearate, crospovidone, talc, lactose monohydrate.
Drug Interactions
Carvedilol may potentiate the effects of other simultaneously taken antihypertensive drugs or drugs that have a hypotensive effect (nitrates).
With the combined use of carvedilol and diltiazem, cardiac conduction disturbances and hemodynamic disturbances may develop.
With the simultaneous administration of carvedilol and digoxin, the concentration of the latter increases and the time of AV administration may increase.
Carvedilol can potentiate the effects of insulin and oral hypoglycemic agents, while the symptoms of hypoglycemia (especially tachycardia) can be masked, so it is recommended that patients with diabetes have regular monitoring of blood sugar levels.
Microsomal oxidation inhibitors (cimetidine) enhance and inducers (phenobarbital, rifampicin) weaken the hypotensive effect of carvedilol.
Catecholamine-lowering drugs (reserpine, MAO inhibitors) increase the risk of hypotension and severe bradycardia.
With the simultaneous use of cyclosporine, the concentration of the latter increases (correction of the daily dose of cyclosporine is recommended).
Concomitant administration of clonidine can potentiate the antihypertensive and heart-rate-reducing effects of carvedilol.
General anesthetics enhance the negative inotropic and hypotensive effect of carvedilol.
Overdose
Symptoms: decreased blood pressure (accompanied by dizziness or fainting), bradycardia. Shortness of breath due to bronchospasm and vomiting may occur. In severe cases cardiogenic shock, respiratory distress, confusion, conductivity disorders are possible.
Treatment: It is necessary to monitor and correct vital indicators, if necessary - in OIT. Symptomatic therapy is carried out. It is advisable to / in the introduction of m-cholin blockers (atropine), adrenomimetics (epinephrine, norepinephrine).
Storage Conditions
The product should be stored out of the reach of children, in a dry, dark place at a temperature not exceeding 25 РC.
Shelf life
2 years.
Terms and conditions
prescription
dosage form
tablets
Possible product names
Vedicardol 6.25mg No. 30
Vedicardol 6.25mg Tab. X30 (R)
VEDICARDOL TAB. 6.25MG No. 30
Vedicardol tablets 6.25 mg, 30 pcs.
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review